Bank of New York Mellon Corp Makes New $6.63 Million Investment in Inspire Medical Systems, Inc. $INSP

Key Points

• Bank of New York Mellon acquired 148,627 shares of Inspire Medical Systems worth approximately $6.63 million, representing about 0.52% of the company. Institutional investors collectively own 94.91% of INSP.
• Inspire reported quarterly EPS of $0.14, beating estimates by $0.38, while revenue of $200.58 million exceeded expectations but declined 7.6% year over year. The company provided fiscal 2026 EPS guidance of $1.05–$1.45.
• INSP shares opened at $61.93, while analysts maintain an average “Hold” rating with a $66.19 price target; recent ratings range from “Strong Buy” to “Sell.”

Bank of New York Mellon Corp acquired a new stake in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 148,627 shares of the company's stock, valued at approximately $6,630,000. Bank of New York Mellon Corp owned approximately 0.52% of Inspire Medical Systems as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. GSA Capital Partners LLP purchased a new stake in shares of Inspire Medical Systems during the second quarter worth about $820,000. Handelsbanken Fonder AB boosted its holdings in Inspire Medical Systems by 44.9% in the second quarter. Handelsbanken Fonder AB now owns 14,200 shares of the company's stock valued at $633,000 after purchasing an additional 4,400 shares during the last quarter. Tactive Advisors LLC acquired a new stake in Inspire Medical Systems during the 2nd quarter valued at approximately $287,000. Assenagon Asset Management S.A. increased its holdings in Inspire Medical Systems by 66.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 864,395 shares of the company's stock worth $38,561,000 after purchasing an additional 344,221 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in Inspire Medical Systems by 85.0% during the 2nd quarter. GAMMA Investing LLC now owns 1,221 shares of the company's stock worth $54,000 after purchasing an additional 561 shares during the last quarter. Hedge funds and other institutional investors own 94.91% of the company's stock.

Inspire Medical Systems Trading Down 1.8%

INSP stock opened at $61.93 on Friday. The firm has a market cap of $1.79 billion, a P/E ratio of 13.40, a P/E/G ratio of 4.79 and a beta of 0.70. Inspire Medical Systems, Inc. has a 12-month low of $38.91 and a 12-month high of $147.03. The stock's 50 day simple moving average is $54.70 and its 200 day simple moving average is $52.36.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The company reported $0.14 EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.38. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The firm had revenue of $200.58 million during the quarter, compared to the consensus estimate of $194.72 million. During the same quarter in the previous year, the company posted $0.45 earnings per share. The firm's revenue was down 7.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. On average, research analysts forecast that Inspire Medical Systems, Inc. will post 1.24 EPS for the current fiscal year.

Insider Activity at Inspire Medical Systems

In related news, insider Jason Kelly sold 963 shares of the business's stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $59.55, for a total transaction of $57,346.65. Following the completion of the sale, the insider owned 18,985 shares of the company's stock, valued at $1,130,556.75. This represents a 4.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 2.20% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on INSP. Weiss Ratings raised Inspire Medical Systems from a "sell (d)" rating to a "sell (d+)" rating in a research report on Wednesday, August 19th. Bank of America lowered shares of Inspire Medical Systems from a "neutral" rating to an "underperform" rating and set a $39.00 price target for the company. in a research note on Friday, May 22nd. Evercore set a $54.00 price target on shares of Inspire Medical Systems in a report on Tuesday, August 4th. UBS Group assumed coverage on shares of Inspire Medical Systems in a report on Tuesday, July 28th. They set a "sell" rating and a $39.00 price objective for the company. Finally, Truist Financial reissued a "hold" rating and issued a $62.00 target price (up from $54.00) on shares of Inspire Medical Systems in a research report on Tuesday, August 4th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the company's stock. According to MarketBeat.com, Inspire Medical Systems presently has an average rating of "Hold" and an average target price of $66.19.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.